TAVI-in-TAVI with Balloon-Expandable Valves

TAVI (Transcatheter Aortic Valve Implantation) has proven to be beneficial and is currently performed in increasingly younger and lower-risk patients. However, as with surgical bioprostheses, structural deterioration, whether due to stenosis or regurgitation, is one of the challenges we must address. 

TAVI-in-TAVI con válvulas balón expandibles

While currently uncommon, this is an issue we will probably see more and more frequently in the future, and its resolution will become a challenge. It might require explant surgery or a new percutaneous valve implantation. Currently, we have very few reports on the latter strategy.

Researchers conducted an analysis of the STS/ACC TVT Registry, which included 350,591 patients who underwent TAVI with balloon-expandable valves (SAPIEN, SAPIEN XT, SAPIEN 3, and SAPIEN 3 Ultra). Of these patients, 1320 (0.37%) underwent TAVI-in-TAVI. About 36.8% of the previous TAVI procedures had been performed with self-expandable valves, while the rest had been conducted with balloon-expandable valves.

The primary endpoint (PEP) of this study was death and stroke at 30 days and one year.

Since patient populations were different, propensity score matching was used, resulting in 1320 patients in each group.

Read also: ROTA.shock Outcomes: Intravascular Lithotripsy vs. Rotational Atherectomy.

The average patient age was 78 years, and 42% of subjects were women; 92% had hypertension, 39% had diabetes, 47% had atrial fibrillation, 30% had a permanent pacemaker, 25% had experienced an infarction, 24% had cardiac conduction disease, and the ejection fraction was 51%. The STS mortality score was 8%.

The mean time between the previous TAVI and TAVI-in-TAVI was 28 months.

Most procedures were performed via the transfemoral access route and were elective.

There were no significant differences in the PEP at 30 days or one year (4.7% vs. 4.0%; hazard ratio [HR], 1.19 [95% confidence interval (CI), 0.82–1.83]; p=0.36; and 17.5% vs. 19.0%; HR, 0.94 [95% CI, 0.77–1.16]; p=0.57, respectively). There were also no differences in death, stroke, the combination of death and stroke, rehospitalization, the need for a permanent pacemaker, infarction, new atrial fibrillation, life-threatening bleeding, functional class improvement, or quality of life improvement.

Read also: What to Do in Cases of AMI with Multivessel Disease.

The gradient at 30 days and one year was higher in those who underwent TAVI-in-TAVI (15.2 mm Hg [SD, 8.0] vs. 11.6 mm Hg [4.7], p<0.0001, and 15.1 mm Hg [8.2] vs. 11.8 mm Hg [5.8], p<0.0001, respectively), although there were no differences in the presence of moderate or severe paravalvular leak.

The analysis also looked at whether the type of valve (self-expandable or balloon-expandable) used in the initial TAVI procedure had an impact on outcomes at 30 days and one year. There were no differences in mortality, stroke, or paravalvular leak, but patients who had received a self-expandable valve had a lower gradient (16.6 mm Hg [SD, 8.6] vs. 14.2 mm Hg [7.5], p<0.0001, and 17.1 mm Hg [9.2] vs. 13.6 mm Hg [7.1], p=0.0001, respectively).

Conclusion

In conclusion, TAVI-in-TAVI with balloon-expandable valves proved to be effective in treating TAVI dysfunction, with a low rate of complications and similar rates of death and stroke compared with the initial TAVI procedure. Patients who underwent TAVI-in-TAVI had a clinical profile similar to that of patients who underwent TAVI for native aortic valve stenosis. Therefore, TAVI-in-TAVI with balloon-expandable valves could be considered a reasonable option for treating TAVI failure in a selected group of patients.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves: a registry study.

Reference: Raj R Makkar, et al. The Lancet  Published online August 31, 2023 https://doi.org/10.1016 S0140-6736(23)01636-7.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...